Qingdao Vland Biotech INC.

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
12.09 ^CNY	-1.23%		-2.11%	-20.57%

05-07	China stocks edge down; HK shares fall after 10-day winning streak	RE
04-25	Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Qingdao Vland Biotech INC. has completed an IPO in the amount of CNY 394.01673 million.

January 09, 2019 at 12:00 am

Qingdao Vland Biotech INC. has completed an IPO in the amount of CNY 394.01673 million.

Security Name: A Shares
Security Type: Common Stock
Securities Offered: 38,667,000
PriceRange: CNY 10.19

Latest news about Qingdao Vland Biotech INC.

China stocks edge down; HK shares fall after 10-day winning streak	05-07	RE
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik	23-10-13	MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.	23-08-15	CI
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan	23-07-21	MT
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.	23-07-20	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant	23-03-24	MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-23	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-19	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.	21-10-18	CI
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group	21-10-18	MT
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-16	CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-20	CI
Qingdao Vland Biotech INC. announced that it has received CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd.	21-04-06	CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-28	CI
Qingdao Vland Biotech INC. announced that it expects to receive CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd.	20-10-15	CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-26	CI

Chart Qingdao Vland Biotech INC.

Duration

Period

More charts

Qingdao Vland Biotech Co., Ltd. is a China-based company which mainly develops, produces and sells enzyme preparations, micro-ecology and animal health products. The Company's main products are enzyme preparations, micro-ecology and animal health products, such as feed enzymes, industrial enzymes, food enzymes, plant micro-ecological preparations, veterinary chemicals and veterinary drugs. The Company's products are mainly used in the washing, textile, food, feed, paper, energy and pharmaceutical industries. The Company mainly distributes its products in China and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Qingdao Vland Biotech INC.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.09

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
QINGDAO VLAND BIOTECH INC.	-20.57%	426M
VERTEX PHARMACEUTICALS INCORPORATED	+20.04%	126B
REGENERON PHARMACEUTICALS, INC.	+23.27%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.32%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-13.50%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.84%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.19%	14.08B

Bio Therapeutic Drugs